TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18482867
Drug: Valerian (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian (300 mg nightly for 2 weeks)
Study: 11332873
Drug: Amoxicilina 250
Normalized name: Amoxicilina
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicilina 250 mg/5 ml oral suspension
Study: 11332873
Drug: Amoxicilina 500
Normalized name: Amoxicilina
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicilina 500 mg capsule
Study: 11332873
Drug: Amoxil 250
Normalized name: Amoxil 250mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxil 250 mg/5 ml oral suspension
Study: 11332873
Drug: Amoxil capsule
Normalized name: Amoxi Drop
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxil capsule 500 mg
Study: 2685676
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous oxytocin infusion
Study: 2685676
Drug: Pulsatile intravenous
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile intravenous oxytocin infusion (every 8 minutes)
Study: 3404378
Drug: Pulsatile intravenous
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile intravenous oxytocin infusion
Study: 23545926
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid with lidocaine (HA+L)
Study: 23545926
Drug: Both HA
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both HA and HA+L
Study: 8764799
Drug: 50 micrograms/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms/ml latanoprost once daily
Study: 8764799
Drug: 15 micrograms/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 micrograms/ml latanoprost twice daily
Study: 30796036
Drug: Trastuzumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab treatment (after exclusion of lowest HER2 expressers)
Study: 26435365
Drug: Insulin degludec/insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin degludec/insulin aspart
Study: 27009108
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart 30
Study: 25007693
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine 100 microgram/kg before skin incision
Study: 25007693
Drug: Ilioinguinal/iliohypogastric nerve
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilioinguinal/iliohypogastric nerve block with 0.25 ml/kg bupivacaine 0.5% before skin incision
Study: 23158942
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine for promoting blood circulation and removing blood stasis
Study: 19283561
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low dose naltrexone (VLNTX) 0.125 or 0.250 mg per day
Study: 19283561
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low dose naltrexone (VLNTX)
Study: 17224720
Drug: Tiagabine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (4 mg/d initiated, titrated to a maximum of 16 mg/d)
Study: 2723116
Drug: HP 029
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP 029 (5 to 200 mg)
Study: 27322814
Drug: Bosentan (ET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (ET receptor antagonist)
Study: 26571885
Drug: Floating-needle therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Floating-needle therapy combined with rehabilitation training
Study: 24211338
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) + Light therapy (CBT + LT)
Study: 17033231
Drug: UFT+TAM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT+TAM therapy
Study: 17033231
Drug: CAF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF therapy
Study: 9366769
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose in lactated Ringer's solution (D5RL)
Study: 1412183
Drug: Warfarin, INR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin, INR = 2.5 - 4.2 (n = 34)
Study: 1412183
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA), 300 mg/d (n = 30)
Study: 19357113
Drug: Pamapimod (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamapimod (up to 300 mg once daily)
Study: 17022846
Drug: Rapidly absorbed
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapidly absorbed paracetamol tablet (PS)
Study: 17022846
Drug: Standard paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard paracetamol tablet (P)
Study: 15663607
Drug: Zolmitriptan 5
Normalized name: zolmitriptan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan 5 mg nasal spray
Study: 7490815
Drug: 5.4 mg
Normalized name: pectin 5.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.4 mg yohimbine plus 10 mg isoxsuprine 3 times daily
Study: 7490815
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg pentoxifylline 3 times daily
Study: 1416272
Drug: Group EF:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group EF: 5 micrograms.kg‐1 of fentanyl followed by 0.3 mg.kg‐1 of etomidate.
Study: 31704108
Drug: Fresh Empire
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh Empire campaign treatment
Study: 25962788
Drug: Integrated motivational
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated motivational interviewing and cognitive behavioural therapy
Study: 17066118
Drug: Non-steroid group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroid group (combined Group I and II)
Study: 17066118
Drug: Steroid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid group (combined Group III and IV)
Study: 8446670
Drug: Ondansetron 0.15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.15, 0.3, or 0.45 mg/kg
Study: 8446670
Drug: Ondansetron 0.01,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.01, 0.02, or 0.04 mg/kg
Study: 8446670
Drug: Ondansetron (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (various doses)
Study: 2949169
Drug: Doxazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (1 mg daily, titrated to double every two weeks)
Study: 2949169
Drug: Doxazosin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (8 weeks treatment)
Study: 24518180
Drug: IDeg 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDeg 200 U/mL
Study: 24518180
Drug: IDeg 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDeg 100 U/mL
Study: 22983778
Drug: Titrated intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated intravenous norepinephrine (NE) infusion
Study: 18042473
Drug: Formoterol fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol fumarate inhalation solution 20 microg BID via nebulizer (FFIS)
Study: 7762533
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) for 6 months
Study: 29931459
Drug: Vitamin D3,
Normalized name: Vitamin D3, 25 mcg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3, 70 µg (2800 IU)/day for three months
Study: 19923079
Drug: Coopdech endobronchial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coopdech endobronchial blocker tube (BB)
Study: 17846932
Drug: Insulin only
Normalized name: Isophane insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin only (IO)
Study: 17846932
Drug: Bedtime insulin
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime insulin with sulphonylurea (IS)
Study: 17846932
Drug: Bedtime insulin
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime insulin with metformin (IM)
Study: 12187213
Drug: Single 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 500 mg oral dose of levofloxacin
Study: 12187213
Drug: Additional doses
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional doses of levofloxacin for high-risk patients
Study: 10542974
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone Propionate (FP) 2000 micrograms daily via Diskhaler
Study: 10542974
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 2000 micrograms daily via Turbuhaler
Study: 23351277
Drug: Acetaminophen elixir
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen elixir (10-15 mg/kg)
Study: 23351277
Drug: Acetaminophen suppository
Normalized name: acetaminophen Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen suppository (10-15 mg/kg)
Study: 19477353
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg atorvastatin daily for 12 weeks
Study: 19477353
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg atorvastatin daily for 12 weeks
Study: 16451147
Drug: 80% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80% oxygen in nitrogen and saline 2 ml intravenously (i.v.) at the end of surgery (group 80)
Study: 16451147
Drug: 30% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% oxygen in nitrogen and saline 2 ml intravenously (i.v.) at the end of surgery (group 30)
Study: 16451147
Drug: 30% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% oxygen in nitrogen and ondansetron 4 mg (group O)
Study: 16451147
Drug: 80% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80% oxygen in nitrogen and saline 2 ml intravenously (i.v.) (group 80)
Study: 15225176
Drug: 3-day rabeprazole-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day rabeprazole-based treatment (rabeprazole 20 mg b.d., amoxicillin 1000 mg b.d., clarithromycin 500 mg b.d.)
Study: 15225176
Drug: 7-day rabeprazole-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day rabeprazole-based treatment (rabeprazole 20 mg b.d., amoxicillin 1000 mg b.d., clarithromycin 500 mg b.d.)
Study: 15225176
Drug: 10-day rabeprazole-based
Normalized name: rabeprazole sodium 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day rabeprazole-based treatment (rabeprazole 20 mg b.d., amoxicillin 1000 mg b.d., clarithromycin 500 mg b.d.)
Study: 15225176
Drug: 10-day omeprazole-based
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day omeprazole-based treatment (omeprazole 20 mg b.d., amoxicillin 1000 mg b.d., clarithromycin 500 mg b.d.)
Study: 2286005
Drug: Sulfadoxine 25
Normalized name: pyrimethamine-sulfadoxine 25 mg-500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine 25 mg/kg + Pyrimethamine 1.25 mg/kg as a single dose (S + P)
Study: 2286005
Drug: Amodiaquine 10
Normalized name: amodiaquine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine 10 + 10 + 5 mg/kg over three days with Sulfadoxine + Pyrimethamine on the third day (A + S + P)
Study: 7015798
Drug: Methyldopa (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (250 mg thrice a day)
Study: 27930383
Drug: E-OJ-01 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-OJ-01 (400 mg for 56 days)
Study: 17952657
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of cannabinoids
Study: 7924177
Drug: L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (2 gm per day for 22 weeks)
Study: 7924177
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs only (Control for subgroup A1)
Study: 7924177
Drug: L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (2 gm per day for 10 weeks)
Study: 7924177
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs only (Control for subgroup A2)
Study: 22538532
Drug: Aspirin 500
Normalized name: aspirin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 500 mg/d
Study: 20826169
Drug: Protein-rich supplements
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-rich supplements (n=12)
Study: 20826169
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (isocaloric combination of carbohydrate and fat supplements, n=4)
Study: 11049908
Drug: Epinephrine-15 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine-15 group (3 mL of 1.5% lidocaine containing 15 microg of epinephrine)
Study: 11049908
Drug: Epinephrine-10 group
Normalized name: epinephrine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine-10 group (2 mL of 1.5% lidocaine containing 10 microg of epinephrine)
Study: 11049908
Drug: Epinephrine-5 group
Normalized name: epinephrine 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine-5 group (1 mL of 1.5% lidocaine containing 5 microg of epinephrine)
Study: 8922195
Drug: Vinorelbine (VRB)
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine (VRB) at a dose of 25 mg/m2 weekly
Study: 8922195
Drug: Vindesine (VDS)
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vindesine (VDS) at a dose of 3 mg/m2 weekly
Study: 2859900
Drug: Almitrine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine (3 mg X kg‐1)
Study: 2859900
Drug: Almitrine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine (1.5 mg X kg‐1 X day‐1) for four weeks
Study: 24894625
Drug: Top 30%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Top 30% antibody responders with NicVAX
Study: 24894625
Drug: Top 30%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Top 30% antibody responders with Placebo
Study: 22722614
Drug: TENS vs
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS vs Acetaminophen
Study: 20376002
Drug: Almorexant (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almorexant (doses of 400 mg and above)
Study: 20376002
Drug: Almorexant (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almorexant (500 mg)
Study: 12190961
Drug: Micronised oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised oestradiol (E2) 2 mg daily (n = 16)
Study: 12190961
Drug: Combined HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined HRT (2 mg E2 daily with trimegestone 0.5 mg daily or dydrogesterone 10 mg daily) (n = 28)
Study: 10208189
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (albuterol 10 mg/h plus ipratropium bromide 1.0 mg/h)
Study: 10208189
Drug: Albuterol alone
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol alone (control)
Study: 649240
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of papaverine
Study: 649240
Drug: 1.0 ml
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml of physiological saline (placebo)
Study: 15666492
Drug: Irbesartan (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (300 mg/die)
Study: 15666492
Drug: Chlortalidone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlortalidone (50 mg/die)
Study: 12495257
Drug: Iron-folate tablets
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron-folate tablets (200 mg FeSO4 and 250 microg folic acid) + 5 mg riboflavin (group IFR)
Study: 12495257
Drug: Iron-folate tablets
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron-folate tablets (200 mg FeSO4 and 250 microg folic acid) + 2.75 mg retinyl palmitate (equal to 5000 IU vitamin A) (group IFA)
Study: 12495257
Drug: Iron-folate tablets
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron-folate tablets (200 mg FeSO4 and 250 microg folic acid) + 5 mg riboflavin + 2.75 mg retinyl palmitate (group IFRA)
Study: 12495257
Drug: Iron-folate tablets
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron-folate tablets (200 mg FeSO4 and 250 microg folic acid) + 5 mg glucose (group IF)
Study: 8595510
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with 3TC (300 mg b.i.d.) plus AZT (200 mg t.i.d.) for 24 weeks
Study: 8595510
Drug: AZT monotherapy
Normalized name: AZT
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AZT monotherapy (200 mg t.i.d.)
Study: 8595510
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with 3TC (300 mg b.i.d.) plus AZT (200 mg t.i.d.)
Study: 8595510
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with 3TC (150 mg b.i.d.) plus AZT (200 mg t.i.d.)
Study: 8595510
Drug: AZT monotherapy
Normalized name: AZT
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AZT monotherapy (200 mg t.i.d. plus placebo)
Study: 8595510
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with AZT and 3TC
Study: 2651031
Drug: Multiple injection
Normalized name: sodium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple injection technique (MIT)
Study: 28847751
Drug: GED‐0301 (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: GED‐0301 (160 mg/day) for 4 weeks
Study: 28847751
Drug: GED‐0301 (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: GED‐0301 (160 mg/day) for 8 weeks
Study: 28847751
Drug: GED‐0301 (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: GED‐0301 (160 mg/day) for 12 weeks
Study: 11920488
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones (40 mg genistein per day)
Study: 6669927
Drug: Instilled fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instilled fluid volumes of 2.5, 5, 10, and 15 ml at pH 1.0, 4.0, or 7.0
Study: 29176540
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pills (OCP)
Study: 31843854
Drug: HealthTracker-based structured
Approvals — FDA: no, EMA: no, PMDA: no
Description: HealthTracker-based structured medication review tool
Study: 22565284
Drug: CCCL ALL
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCCL ALL protocol (risk-adapted therapy)
Study: 7750020
Drug: Salmon calcitonin
Normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon calcitonin (100 IU/day i.m. plus 500 mg of elemental calcium for 10 days each month)
Study: 7750020
Drug: Elemental calcium
Normalized name: Elemental calcium
DrugBank: Calcium (DB01373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental calcium (500 mg for 10 days each month)
Study: 2105985
Drug: Ketorolac 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 2% gel
Study: 7041813
Drug: Cefonicid, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefonicid, 1 g daily (21 cases)
Study: 7041813
Drug: Cefamandole, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole, 1 g every 6 h (12 cases)
Study: 31663620
Drug: DOX–MNPs treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOX–MNPs treatment
Study: 31663620
Drug: Avasimibe combined
Normalized name: Avasimibe
DrugBank: Avasimibe (DB06442)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avasimibe combined with DOX–MNPs treatment
Study: 28009106
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri DSM 17938 (high dose 1010 CFU/d)
Study: 28009106
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri DSM 17938 (low dose 108 CFU/d)
Study: 25591799
Drug: Tivozanib 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivozanib 0.5 mg with mFOLFOX-6
Study: 25591799
Drug: Tivozanib 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivozanib 1.5 mg with mFOLFOX-6
Study: 25618969
Drug: Xinfeng capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinfeng capsules (XFC)
Study: 10430010
Drug: Estriol suppositories
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estriol suppositories
Study: 8685642
Drug: Fluconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (100 mg b.i.d. per os)
Study: 8685642
Drug: Itraconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (100 mg b.i.d. per os)
Study: 2097908
Drug: Midazolam 0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.35 mg/kg (Group B)
Study: 2097908
Drug: Midazolam 0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.45 mg/kg (Group C)
Study: 7439520
Drug: 2% fusidic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% fusidic acid cream
Study: 20361381
Drug: Pediatric granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric granule formulation of artesunate-mefloquine
Study: 20361381
Drug: Co-blister tablet
Normalized name: Blister Armour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-blister tablet formulation
Study: 16356228
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (blood glucose between 80 and 110 mg/dl)